

Current recommendations and recent progress in endo

Ca-A Cancer Journal for Clinicians

69, 258-279

DOI: [10.3322/caac.21561](https://doi.org/10.3322/caac.21561)

Citation Report

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
2	Integrated analysis of immune-related genes in endometrial carcinoma. <i>Cancer Cell International</i> , 2020, 20, 477.	1.8	10
3	Identification of prognostic and immune-related gene signatures in the tumor microenvironment of endometrial cancer. <i>International Immunopharmacology</i> , 2020, 88, 106931.	1.7	21
4	Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 748-748.	0.7	17
5	ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro. <i>Frontiers in Oncology</i> , 2020, 10, 577141.	1.3	12
6	Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability. <i>Cancers</i> , 2020, 12, 3319.	1.7	59
7	<p>Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11549-11569.	1.0	6
8	Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1340-1346.	1.2	10
9	Diosmetin enhances the sensitivity of radiotherapy by suppressing homologous recombination in endometrial cancer. <i>Cell Cycle</i> , 2020, 19, 3115-3126.	1.3	2
10	Identification of a metabolism-related gene expression prognostic model in endometrial carcinoma patients. <i>BMC Cancer</i> , 2020, 20, 864.	1.1	21
11	Exploration of a novel prognostic risk signatures and immune checkpoint molecules in endometrial carcinoma microenvironment. <i>Genomics</i> , 2020, 112, 3117-3134.	1.3	35
12	ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153032.	1.0	13
13	Determination of novel biomarkers and pathways shared by colorectal cancer and endometrial cancer via comprehensive bioinformatics analysis. <i>Informatics in Medicine Unlocked</i> , 2020, 20, 100376.	1.9	7
14	NORAD orchestrates endometrial cancer progression by sequestering FUBP1 nuclear localization to promote cell apoptosis. <i>Cell Death and Disease</i> , 2020, 11, 473.	2.7	20
15	Clinicopathological study of organ metastasis in endometrial cancer. <i>Future Oncology</i> , 2020, 16, 525-540.	1.1	35
16	Development of an immune gene prognostic classifier for survival prediction and respond to immuncheckpoint inhibitor therapy/chemotherapy in endometrial cancer. <i>International Immunopharmacology</i> , 2020, 86, 106735.	1.7	16
17	Polymorphisms in IL‑1A are associated with endometrial cancer susceptibility among Chinese Han population: A case‑control study. <i>International Journal of Immunogenetics</i> , 2020, 47, 169-174.	0.8	7
18	The value of the apparent diffusion coefficient in differentiating type II from type I endometrial carcinoma. <i>Acta Radiologica</i> , 2021, 62, 959-965.	0.5	8

#	ARTICLE	IF	CITATIONS
19	Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 914-919.	1.2	17
20	Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100660.	1.0	27
21	Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?. <i>Oncology Research and Treatment</i> , 2021, 44, 43-51.	0.8	0
22	Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer. <i>Gynecologic Oncology</i> , 2021, 160, 295-301.	0.6	0
23	Development of a patient-derived explant model for prediction of drug responses in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 160, 557-567.	0.6	6
24	NORAD, a critical long non-coding RNA in human cancers. <i>Life Sciences</i> , 2021, 264, 118665.	2.0	48
25	High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 23.	0.1	0
26	Operative and Oncological Outcomes Comparing Sentinel Node Mapping and Systematic Lymphadenectomy in Endometrial Cancer Staging: Meta-Analysis With Trial Sequential Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 580128.	1.3	10
27	Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China. <i>International Journal of Medical Sciences</i> , 2021, 18, 3082-3089.	1.1	0
28	Differential Expressions of Ki-67, Bcl-2, and Apoptosis Index in Endometrial Cells of Women With and Without Type II Diabetes Mellitus and Their Correlation with Clinicopathological Variables. <i>Reproductive Sciences</i> , 2021, 28, 1447-1456.	1.1	2
29	Artesunate Suppresses the Proliferation and Development of Estrogen Receptor- α -Positive Endometrial Cancer in HAND2-Dependent Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 606969.	1.8	7
30	Literature Review and Our Experience With Bleomycin-Based Electrochemotherapy for Cutaneous Vulvar Metastases From Endometrial Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110101.	0.8	5
31	NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. <i>International Journal of Biological Sciences</i> , 2021, 17, 3428-3440.	2.6	45
32	Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma. <i>International Journal of Biological Sciences</i> , 2021, 17, 448-459.	2.6	26
33	Prospective Non-randomized Control Trial on Role of Systematic High Para-Aortic Lymphadenectomy in Endometrial Cancer: Indian Study. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.1	0
34	Dioscin inhibits human endometrial carcinoma proliferation via G0/G1 cell cycle arrest and mitochondrial-dependent signaling pathway. <i>Food and Chemical Toxicology</i> , 2021, 148, 111941.	1.8	30
35	Novelties of ultrasound imaging for endometrial cancer preoperative workup. <i>Minerva Medica</i> , 2021, 112, 3-11.	0.3	31
36	The impact of Ki-67 index, squamous differentiation and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 549-554.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Surgical treatment and fertility perservation in endometrial cancer. <i>Radiology and Oncology</i> , 2021, 55, 144-149.	0.6	7
38	Histomolecular features of high-grade endometrial cancers. <i>Minerva Medica</i> , 2021, 112, 20-30.	0.3	3
39	Mechanisms of Cisplatin in Combination with Repurposed Drugs against Human Endometrial Carcinoma Cells. <i>Life</i> , 2021, 11, 160.	1.1	9
40	Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100700.	0.3	2
41	The Prognostic Value of Retroperitoneal Lymphadenectomy in Apparent Stage IA Endometrial Endometrioid Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 618499.	1.3	2
42	In search for biomarkers and potential drug targets for uterine serous endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1647-1658.	1.2	5
43	A comprehensive review on the carcinogenic potential of bisphenol A: clues and evidence. <i>Environmental Science and Pollution Research</i> , 2021, 28, 19643-19663.	2.7	63
44	LncRNA ZNF1 stabilizes P21 expression in endometrioid endometrial carcinoma by inhibiting ubiquitination-mediated degradation and regulating the miR378a/PCDHA3 axis. <i>Molecular Oncology</i> , 2022, 16, 813-829.	2.1	11
45	Clinical relevance of oncogenic driver mutations identified in endometrial carcinoma. <i>Translational Oncology</i> , 2021, 14, 101010.	1.7	19
46	Small Non-Coding-RNA in Gynecological Malignancies. <i>Cancers</i> , 2021, 13, 1085.	1.7	20
47	Mortality and glycemc control among patients with diabetes mellitus and uterine or ovarian cancer. <i>Future Science OA</i> , 2021, 7, FSO670.	0.9	4
48	Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis. <i>Diagnostic Pathology</i> , 2021, 16, 28.	0.9	11
49	Identification of Tumor Microenvironment-Related Alternative Splicing Events to Predict the Prognosis of Endometrial Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 645912.	1.3	4
50	Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions. <i>ACS Infectious Diseases</i> , 2021, 7, 987-1009.	1.8	32
51	Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 551-551.	0.7	5
52	The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation. <i>Cell Death and Disease</i> , 2021, 12, 351.	2.7	22
53	Network Pharmacology Analysis and Experimental Pharmacology Study Explore the Mechanism of Gambogic Acid against Endometrial Cancer. <i>ACS Omega</i> , 2021, 6, 10944-10952.	1.6	12
54	Competing risk nomogram predicting cancer-specific mortality for endometrial cancer patients treated with hysterectomy. <i>Cancer Medicine</i> , 2021, 10, 3205-3213.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	7
56	Is routine frozen section analysis necessary in patients with non-endometrioid cancer or grade 3 endometrioid cancer?. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	1.0	1
57	A Prediction Model of Endometrial Cancer Lesion Metastasis under Region of Interest Target Detection Algorithm. <i>Scientific Programming</i> , 2021, 2021, 1-7.	0.5	5
58	N ⁶ -methyladenosine Steers RNA Metabolism and Regulation in Cancer. <i>Cancer Communications</i> , 2021, 41, 538-559.	3.7	24
59	Fatty Acid-Binding Protein 4 (FABP4) Suppresses Proliferation and Migration of Endometrial Cancer Cells via PI3K/Akt Pathway. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3929-3942.	1.0	7
60	OLA1 is a potential prognostic molecular biomarker for endometrial cancer and promotes tumor progression. <i>Oncology Letters</i> , 2021, 22, 576.	0.8	5
61	Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer. <i>Aging</i> , 2021, 13, 16287-16315.	1.4	19
62	Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 787-794.	0.6	17
63	Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma. <i>Aging</i> , 2021, 13, 16696-16712.	1.4	11
64	Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review. <i>Frontiers in Oncology</i> , 2021, 11, 701758.	1.3	20
65	Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. <i>Cancers</i> , 2021, 13, 2901.	1.7	31
66	Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 216.	3.5	53
67	An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients. <i>BioMedical Engineering OnLine</i> , 2021, 20, 64.	1.3	2
68	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
69	Identification of an immune signature to predict poor clinical outcome in cervical cancer. <i>Epigenomics</i> , 2021, 13, 891-907.	1.0	2
70	Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. <i>Oncologist</i> , 2021, 26, e1599-e1608.	1.9	18
71	Endometrial cancer from early to advanced-stage disease: an update for radiologists. <i>Abdominal Radiology</i> , 2021, 46, 5325-5336.	1.0	12
72	Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 671736.	1.8	6

#	ARTICLE	IF	CITATIONS
73	The Role of miRNAs in the Regulation of Endometrial Cancer Invasiveness and Metastasis—A Systematic Review. <i>Cancers</i> , 2021, 13, 3393.	1.7	17
74	Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 659.	1.1	17
75	Clinicopathological Characteristics and Prognosis in Endometrial Cancer With Bone Metastasis: A SEER-Based Study of 584 Women. <i>Frontiers in Oncology</i> , 2021, 11, 694718.	1.3	6
76	A ten-gene methylation signature as a novel biomarker for improving prediction of prognosis and indicating gene targets in endometrial cancer. <i>Genomics</i> , 2021, 113, 2032-2044.	1.3	10
77	ZIC2 upregulates lncRNA SNHG12 expression to promote endometrial cancer cell proliferation and migration by activating the Notch signaling pathway. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	9
78	Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8268.	1.8	11
79	Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population. <i>Cancer Epidemiology</i> , 2021, 73, 101934.	0.8	9
80	Antitumor activity of everolimus in recurrent metastatic endometrial cancer with PTEN deletion: a case report. <i>Gland Surgery</i> , 2021, 10, 2585-2590.	0.5	0
81	The modulatory properties of <i>Astragalus membranaceus</i> treatment on endometrial cancer: an integrated pharmacological method. <i>PeerJ</i> , 2021, 9, e11995.	0.9	5
82	The current knowledge concerning solid cancer and therapy. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22900.	1.4	64
83	Adjuvant radiotherapy improves overall survival when added to surgery and chemotherapy for uterine carcinosarcoma: a surveillance, epidemiology, and end results analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2282-2294.	1.0	4
84	Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. <i>Cell Death and Disease</i> , 2021, 12, 818.	2.7	38
85	Effects of m6A RNA methylation regulators on endometrial cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23942.	0.9	17
86	Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers. <i>Clinical Oncology</i> , 2021, 33, 608-615.	0.6	5
87	Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 693-701.	0.8	7
88	Identification of a Four-Gene Signature With Prognostic Significance in Endometrial Cancer Using Weighted-Gene Correlation Network Analysis. <i>Frontiers in Genetics</i> , 2021, 12, 678780.	1.1	9
89	TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer. <i>Cancer Letters</i> , 2021, 515, 14-27.	3.2	7
90	Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 335-347.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer. <i>Pathology and Oncology Research</i> , 2021, 27, 1609936.	0.9	4
92	RISK FACTORS FOR ESTROGEN EXPOSURE IN VARIOUS GRADES OF ENDOMETRIOID CARINOMA. <i>Indonesian Midwifery and Health Sciences Journal</i> , 2021, 4, 40.	0.1	0
93	Oncologic safety of laparoscopic surgery for women with apparent early-stage uterine serous carcinoma: A multi-institutional retrospective cohort study. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 158, 162-171.	1.0	3
94	Diagnostic and prognostic factors, and two nomograms for endometrial cancer patients with bone metastasis. <i>Medicine (United States)</i> , 2021, 100, e27185.	0.4	2
95	Amide proton transfer imaging in differentiation of type II and type I endometrial carcinoma: a pilot study. <i>Japanese Journal of Radiology</i> , 2022, 40, 184-191.	1.0	10
96	Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. <i>Gynecologic Oncology</i> , 2021, 163, 557-562.	0.6	4
97	Trends in Incidence and Mortality Rates of Uterine Cancer in Kentucky. <i>Southern Medical Journal</i> , 2021, 114, 630-635.	0.3	0
98	Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP. <i>Cancer Letters</i> , 2021, 521, 308-321.	3.2	21
99	CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer. <i>Journal of Cancer</i> , 2021, 12, 2206-2215.	1.2	18
100	Upregulation of microRNA miR-141-3p and its prospective targets in endometrial carcinoma: a comprehensive study. <i>Bioengineered</i> , 2021, 12, 2941-2956.	1.4	10
101	Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2962-2976.	0.4	3
102	MRI-Based Radiomic Model for Preoperative Risk stratification in Stage I Endometrial Cancer. <i>Journal of Cancer</i> , 2021, 12, 726-734.	1.2	24
103	Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e043141.	0.8	2
104	An miRNA signature associated with tumor mutation burden in endometrial cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	6
105	Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare. <i>Cancers</i> , 2020, 12, 1292.	1.7	10
106	Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e27.	1.0	8
107	Activating transcription factor 3 inhibits endometrial carcinoma aggressiveness via JunB suppression. <i>International Journal of Oncology</i> , 2020, 57, 707-720.	1.4	8
108	Long non-coding RNA SNHG12 regulates cell proliferation, invasion and migration in endometrial cancer by targeting miR-4429. <i>Molecular Medicine Reports</i> , 2020, 22, 2842-2850.	1.1	6

#	ARTICLE	IF	CITATIONS
109	Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review). <i>Oncology Letters</i> , 2020, 20, 2075-2090.	0.8	10
110	Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	10
111	lncRNA-ZFAS1 promotes the progression of endometrial carcinoma by targeting miR-34b to regulate VEGFA expression. <i>Open Medicine (Poland)</i> , 2021, 16, 1472-1481.	0.6	1
112	Management of preé, perié, and postémenopausal abnormal uterine bleeding: When to perform endometrial sampling?. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 158, 252-259.	1.0	9
113	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	0.8	10
114	Postoperative Systemic Immune-Inflammation Index (SII): A Superior Prognostic Factor of Endometrial Cancer. <i>Frontiers in Surgery</i> , 2021, 8, 704235.	0.6	24
115	Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1705.	2.0	11
117	Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002884.	1.2	2
118	Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences. <i>American Journal of Cancer Research</i> , 2020, 10, 3061-3082.	1.4	1
119	The role of an immune signature for prognosis and immunotherapy response in endometrial cancer. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 532-548.	0.0	4
120	Circular RNA intraflagellar transport 80 facilitates endometrial cancer progression through modulating miR-545-3p/FAM98A signaling. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	7
121	Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e054004.	0.8	1
122	Multimiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
123	Is adaptive treatment planning for single-channel vaginal brachytherapy necessary?. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 687-693.	0.4	0
124	The significance of microsatellite instability in endometrial cancer. <i>Obstetrica Si Ginecologie</i> , 2021, 3, 140.	0.0	0
125	LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. <i>Cancer Letters</i> , 2022, 529, 37-52.	3.2	18
126	Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 812-823.	1.9	3
127	Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer. <i>Cell Death and Disease</i> , 2022, 13, 59.	2.7	8

#	ARTICLE	IF	CITATIONS
128	Establishing a Prognostic Signature Based on Epithelialâ€“Mesenchymal Transition-Related Genes for Endometrial Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 805883.	2.2	11
129	Hybrid PET/MRI in Staging Endometrial Cancer. <i>Clinical Nuclear Medicine</i> , 2022, 47, e221-e229.	0.7	17
130	Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNETâ€“a phase I, single-arm study. , 2022, 10, e003777.		141
131	Recurrence Features and Factors influencing Post-relapse Survival in Early-stage Endometrial Cancer after Adjuvant Radiotherapy. <i>Journal of Cancer</i> , 2022, 13, 202-211.	1.2	2
132	MiR-192-5p-Modified Tumor-Associated Macrophages-Derived Exosome Suppressed Endometrial Cancer Progression Through Targeting IRAK1/NF- κ B Signaling. <i>Reproductive Sciences</i> , 2022, 29, 436-447.	1.1	23
133	Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 793793.	1.8	2
134	Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 827956.	1.3	16
135	Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100401.	1.5	3
136	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	13.9	375
137	The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers. <i>Cancers</i> , 2021, 13, 6102.	1.7	10
138	KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. <i>Molecular Omics</i> , 2022, 18, 506-519.	1.4	4
140	Distinct Roles of m5C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 786266.	1.3	17
141	Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention. <i>Bosnian Journal of Basic Medical Sciences</i> , 2022, , .	0.6	3
142	Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	0.6	0
143	Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma. <i>BMC Cancer</i> , 2022, 22, 325.	1.1	7
144	CircESRP1 enhances metastasis and epithelialâ€“mesenchymal transition in endometrial cancer via the miR-874-3p/CPEB4 axis. <i>Journal of Translational Medicine</i> , 2022, 20, 139.	1.8	11
145	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
146	Expression of CD47 in Endometrial Cancer and Its Clinicopathological Significance. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	3

#	ARTICLE	IF	CITATIONS
147	Systematic Lymphadenectomy and Oncological Outcomes of Women With Apparent Early-Stage Clear Cell Carcinoma of the Endometrium: A Multi-Institutional Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 800957.	1.3	0
148	MRI radiomics: A machine learning approach for the risk stratification of endometrial cancer patients. <i>European Journal of Radiology</i> , 2022, 149, 110226.	1.2	18
149	Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 788431.	2.2	12
150	Endometrial cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 88.	18.1	155
151	Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review. <i>Immunoinformatics</i> , 2021, 3-4, 100008.	1.2	21
152	SPTBN2 regulated by miR-424-5p promotes endometrial cancer progression via CLDN4/PI3K/AKT axis. <i>Cell Death Discovery</i> , 2021, 7, 382.	2.0	12
153	Near-infrared light-triggered nano-prodrug for cancer gas therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 443.	4.2	31
154	Oncological Safety of Laparoscopic Surgery for Women with Apparent Early-stage Uterine Clear Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Journal of Minimally Invasive Gynecology</i> , 2022, 29, 968-975.	0.3	3
155	Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, .	0.8	2
156	Clinical Value Analysis of Combined Vaginal Ultrasound, Magnetic Resonance Dispersion Weighted Imaging, and Multilayer Spiral CT in the Diagnosis of Endometrial Cancer Using Deep VGG-16 AdaBoost Hybrid Classifier. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
157	The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 885114.	1.3	3
158	Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	5
159	Roles and mechanisms of the m6A reader YTHDC1 in biological processes and diseases. <i>Cell Death Discovery</i> , 2022, 8, 237.	2.0	16
160	The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database. <i>Journal of Gynecologic Surgery</i> , 0, , .	0.0	1
161	Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102395.	0.6	5
162	LINC00958: A promising long non-coding RNA related to cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113087.	2.5	8
163	Regulatory mechanism of miR-20a-5p expression in Cancer. <i>Cell Death Discovery</i> , 2022, 8, 262.	2.0	14
164	A novel risk model of SUMOylation-related genes associated with prognosis in endometrial cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0

#	ARTICLE	IF	CITATIONS
165	Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
166	Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-24.	0.6	2
167	Amentoflavone promotes ferroptosis by regulating reactive oxygen species (ROS) /5'AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) to inhibit the malignant progression of endometrial carcinoma cells. <i>Bioengineered</i> , 2022, 13, 13269-13279.	1.4	7
168	Diagnosis and Prediction of Endometrial Carcinoma Using Machine Learning and Artificial Neural Networks Based on Public Databases. <i>Genes</i> , 2022, 13, 935.	1.0	4
169	Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
170	IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	10
171	Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the Effectiveness and quality of Endometrial Cancer Treatment (EFFECT). <i>BMC Cancer</i> , 2022, 22, .	1.1	1
172	Endometrial Cancer-Infiltrating Mesenchymal Stem Cells Exhibit Immunosuppressive Effects. <i>Cell Transplantation</i> , 2022, 31, 096368972211044.	1.2	2
173	Exploring the mechanism and experimental verification of puerarin in the treatment of endometrial carcinoma based on network pharmacology and bioinformatics analysis. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	6
174	Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1847-1863.	2.0	5
175	FoxM1 contributes to progesterin resistance and epithelial-to-mesenchymal transition in endometrial carcinoma. <i>Molecular and Cellular Toxicology</i> , 0, , .	0.8	0
176	Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols: The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6703.	1.8	16
177	Exploration of the Molecular Mechanism of Danzhi Xiaoyao Powder in Endometrial Cancer through Network Pharmacology. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-13.	0.5	1
178	Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. <i>Pathology Research and Practice</i> , 2022, 236, 153990.	1.0	8
179	Effect of demethyltransferase FTO on tumor progression. <i>Biocell</i> , 2022, 46, 2387-2397.	0.4	0
180	Prediction of Factors Associated with Abnormal Uterine Bleeding by Transvaginal Ultrasound Combined with Bleeding Pattern. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-8.	0.7	0
181	Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story. <i>Cancers</i> , 2022, 14, 3238.	1.7	4
182	Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
183	Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer—time to revisit current imaging guidelines?. <i>European Radiology</i> , 2023, 33, 221-232.	2.3	3
184	Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
185	Expression of MCMs in endometrial cancer and its biological correlation analysis. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
186	The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer. <i>Diagnostics</i> , 2022, 12, 1737.	1.3	3
187	Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. <i>Nature Communications</i> , 2022, 13, .	5.8	28
188	Endometrial microbiota from endometrial cancer and paired pericancer tissues in postmenopausal women: differences and clinical relevance. <i>Menopause</i> , 2022, 29, 1168-1175.	0.8	5
189	A new nomogram for predicting lung metastasis in newly diagnosed endometrial carcinoma patients: A study based on SEER. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	1
190	Construction of a miRNA-Based Nomogram Model to Predict the Prognosis of Endometrial Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 1154.	1.1	16
191	Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2022, 166, 582-588.	0.6	7
192	Integrated Bioinformatics Analysis of Serine Racemase as an Independent Prognostic Biomarker in Endometrial Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
193	Machine Learning for Endometrial Cancer Prediction and Prognostication. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
194	Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	7
195	Depleting TMED3 alleviates the development of endometrial carcinoma. <i>Cancer Cell International</i> , 2022, 22, .	1.8	1
196	Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile. <i>Cancers</i> , 2022, 14, 3536.	1.7	3
197	Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3361-3369.	1.2	2
198	<i>FAT2</i> mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	0
199	Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States. <i>Current Medical Research and Opinion</i> , 2022, 38, 1935-1945.	0.9	3
200	A Comprehensive Analysis of Interferon Regulatory Factor Expression: Correlation with Immune Cell Infiltration and Patient Prognosis in Endometrial Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-18.	0.9	1

#	ARTICLE	IF	CITATIONS
201	Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003492.	1.2	5
202	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. <i>Cancer Research Communications</i> , 2022, 2, 1293-1303.	0.7	2
203	m6A mRNA methylation regulates the ERK/NF- κ B/AKT signaling pathway through the PAPP/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer. <i>Cell Biology and Toxicology</i> , 2023, 39, 1611-1626.	2.4	7
204	Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 150, 106274.	1.2	3
205	Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.1	2
206	Endothelial cell-specific molecule 1 (ESM1) promoted by transcription factor SPI1 acts as an oncogene to modulate the malignant phenotype of endometrial cancer. <i>Open Medicine (Poland)</i> , 2022, 17, 1376-1389.	0.6	3
207	NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211127.	0.8	0
208	Prognostic Values From Integrated Analysis of the Nomogram Based on RNA-Binding Proteins and Clinical Factors in Endometrial Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211236.	0.6	3
209	Current Approaches to the Management of Patients with Endometrial Cancer. <i>Cancers</i> , 2022, 14, 4500.	1.7	18
210	The role of intestinal and vaginal dysbiosis in endometrial cancer: an integrative review. <i>International Journal of Nutrology</i> , 2022, 15, .	0.0	1
211	Systematic Analysis of Tumor Microenvironment Patterns and Oxidative Stress Characteristics of Endometrial Carcinoma Mediated by 5-Methylcytosine Regulators. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-25.	1.9	2
212	Cuproptosis patterns and tumor microenvironment in endometrial cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
213	Mechanism investigation and experiment validation of capsaicin on uterine corpus endometrial carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
215	Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
216	Identification of inflammatory-related gene signatures to predict prognosis of endometrial carcinoma. <i>BMC Genomic Data</i> , 2022, 23, .	0.7	1
217	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	0
218	Correlation of Microsatellit Instability with Morphological Findings in Endometrial Carcinomas. <i>Journal of Ankara University Faculty of Medicine</i> , 2022, 75, 322-327.	0.0	0
219	Circular RNAs in endometrial carcinoma (Review). <i>Oncology Reports</i> , 2022, 48, .	1.2	5

#	ARTICLE	IF	CITATIONS
220	High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma. <i>Cell Biology International</i> , 0, , .	1.4	0
221	Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study. <i>Cancers</i> , 2022, 14, 5024.	1.7	2
222	Calcium-Related Genes Predicting Outcomes and Serving as Therapeutic Targets in Endometrial Cancer. <i>Cells</i> , 2022, 11, 3156.	1.8	2
223	RNA m6A methylation regulators in endometrial cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
224	Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114016.	2.5	8
225	Construction of Oxidative Stress-Related Genes Risk Model Predicts the Prognosis of Uterine Corpus Endometrial Cancer Patients. <i>Cancers</i> , 2022, 14, 5572.	1.7	7
226	A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-43.	1.9	2
227	Integrated miRNA and mRNA omics reveal dioscin suppresses migration and invasion via MEK/ERK and JNK signaling pathways in human endometrial carcinoma in vivo and in vitro. <i>Journal of Ethnopharmacology</i> , 2023, 303, 116027.	2.0	5
228	Patterns and trends in the cause of death for patients with endometrial cancer. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	1.4	3
229	ATAD2 Upregulation Promotes Tumor Growth and Angiogenesis in Endometrial Cancer and Is Associated with Its Immune Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-12.	0.6	3
230	Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 155-167.	1.9	9
231	ROMA Index Is an Effective Predictor for Advanced Endometrial Cancer before Surgery. <i>Disease Markers</i> , 2022, 2022, 1-7.	0.6	0
232	<scp>m6A</scp>-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, .	0.9	6
233	Gut and genital tract microbiomes: Dysbiosis and link to gynecological disorders. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	14
234	Gene signature and prognostic value of ubiquitination-related genes in endometrial cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	1
235	Identification of tumour antigens and immune subtypes in the development of an anti-€cancer vaccine for endometrial carcinoma. <i>Scandinavian Journal of Immunology</i> , 0, , .	1.3	0
236	Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
237	A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1675.	1.8	2

#	ARTICLE	IF	CITATIONS
238	The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 34-42.	0.9	4
239	KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
240	Shared sex hormone metabolism-related gene prognostic index between breast and endometrial cancers. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
241	Molecular remission using personalized low-dose immunotherapy with minimal toxicities for poor prognosis hematological and solid tumor cancers. , 2023, , 427-453.		1
242	CD133 as Biomarker and Therapeutic Target in Gynecologic Malignancies. , 2023, , .		1
243	Clinical Significance of Lymphatic Infiltration Detected by Immunohistochemical Double Staining in Patients with Endometrial Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, 117955492311523.	0.6	0
244	Evaluation of immunotherapy efficacy in gynecologic cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
245	SLERT, as a novel biomarker, orchestrates endometrial cancer metastasis via regulation of BDNF/TRKB signaling. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	6
246	Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 16, 481-497.	0.8	4
248	LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma. <i>Life Sciences</i> , 2023, 320, 121512.	2.0	2
249	Necroptosis-Related LncRNA Signatures for Prognostic Prediction in Uterine Corpora Endometrial Cancer. <i>Reproductive Sciences</i> , 2023, 30, 576-589.	1.1	9
250	Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2023, 51, 57-73.	1.9	1
251	Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study. <i>Current Oncology</i> , 2023, 30, 2277-2289.	0.9	3
252	Platycodin D inhibits the proliferation, invasion and migration of endometrial cancer cells by blocking the PI3K/Akt signaling pathway via ADRA2A upregulation. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
253	Association between sarcopenia and survival in patients with gynecologic cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
254	A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	4
255	Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma. <i>Diagnostics</i> , 2023, 13, 870.	1.3	1
256	Human microbiomes in cancer development and therapy. <i>MedComm</i> , 2023, 4, .	3.1	6

#	ARTICLE	IF	CITATIONS
257	Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
258	High expression of TARS is associated with poor prognosis of endometrial cancer. <i>Aging</i> , 0, , .	1.4	2
259	Identification of immunogenic cell death-associated subtypes and characterization of the tumor microenvironment in endometrial cancer. <i>Journal of Gene Medicine</i> , 0, , .	1.4	0
260	Causes of death in endometrial cancer survivors: A Surveillance, Epidemiology, and End Resultâ€‘based analysis. <i>Cancer Medicine</i> , 2023, 12, 10917-10930.	1.3	4
261	An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	7
262	A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311576.	1.4	3
263	Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 361-368.	1.1	1
264	Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physicianâ€™s Choice. <i>European Journal of Cancer</i> , 2023, 186, 172-184.	1.3	2
265	Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6449.	1.8	2
266	Role of microRNAs in glycolysis in gynecological tumors (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	1
267	A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer. <i>Cancer Biology and Therapy</i> , 2023, 24, .	1.5	0
316	Type I Endometrial Cancer: Advanced Stage. , 2023, , 189-194.		0
328	Effects of CLDN9 on Proliferation of Uterine Corpus Endometrioid Carcinoma Cells. , 2023, , .		0